Although high-grade serous ovarian carcinomas (SOCs) comprise the majority of epithelial ovarian cancer, less common subtypes account one third of all cases, many of which are chemoresistant and frequently with wild-type TP53. These histologic subtypes have distinct molecular origins, with correspondingly diverse and specific clinical behaviors; they are treated with the same regimen as high-grade SOC. The gene discussed is TP53; the disease is ovarian serous carcinoma.